Thermo Fisher Scientific Inc (TMO)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $259.44B
Last updated: Nov 17, 2026 at 11:06 AM ET
Thermo Fisher Scientific Inc (TMO) Stock Forecast
Analysts expect Thermo Fisher Scientific (TMO) to earn $25.28 per share in the fiscal year ending Dec 31, 2026, on revenue of $48.01B. Of 27 analysts, 23 rate the stock Buy or Strong Buy, 3 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 23 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 27 ratings average 2.11, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 85% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 11.1% |
| Buy | 20 | 74.1% |
| Hold | 3 | 11.1% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 3.7% |
- Consensus
- Buy
- Total analysts
- 27
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 9.9% and revenue estimates rise 5.3%.
- Fiscal year ending Dec 31, 2026
- $25.28
- EPS consensus, revenue $48.01B
- Fiscal year ending Dec 31, 2027
- $27.78
- EPS consensus, revenue $50.54B
- Next report
- Jan 27, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $25.28 | $25.15 to $25.40 | 27 | $48.01B | $47.85B to $48.22B | 25 |
| Dec 31, 2027 | $27.78 | $27.02 to $29.31 | 27 | $50.54B | $49.94B to $51.48B | 25 |
Quarterly Estimates
The EPS consensus falls from $7.19 for the quarter ending Dec 31, 2026 to $6.05 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $7.19 | $6.86 to $7.62 | 23 | $12.98B | $12.46B to $13.64B | 24 |
| Mar 31, 2027 | $6.05 | $5.64 to $6.53 | 13 | $11.74B | $11.60B to $11.98B | 11 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 49 upward and 8 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 23 | 1 |
| Fiscal year ending Dec 31, 2027 | 20 | 4 |
| Quarter ending Mar 31, 2027 | 6 | 3 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 0.6% from $25.12.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $25.28 | $25.26 | $25.13 | $25.13 | $25.12 | +0.6% |
| Fiscal year ending Dec 31, 2027 | $27.78 | $27.74 | $27.55 | $27.53 | $27.51 | +1.0% |
| Quarter ending Mar 31, 2027 | $6.05 | $6.05 | $5.98 | $6.00 | $6.00 | +0.8% |
Frequently Asked Questions About TMO
What is the TMO stock forecast?
Consensus analyst estimates put Thermo Fisher Scientific's EPS at $25.28 for the fiscal year ending Dec 31, 2026, on revenue of $48.01B. The consensus rating from 27 analysts is Buy.
How do analysts rate TMO stock?
Of 27 analysts covering Thermo Fisher Scientific, 3 rate it Strong Buy, 20 Buy, 3 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from TMO next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $25.28, with estimates from $25.15 to $25.40 from 27 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $27.78, with estimates from $27.02 to $29.31 from 27 analysts.
What revenue do analysts expect from Thermo Fisher Scientific next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $48.01B, with estimates from $47.85B to $48.22B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $50.54B, with estimates from $49.94B to $51.48B.
How many analysts cover TMO?
27 analysts rate Thermo Fisher Scientific stock, and 27 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
TMO pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts